Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01906255 · ClinicalTrials.gov registry record
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 10,577
- Enrollment target
NCT01906255: Completed study, sponsored by Gilead Sciences.
NCT01906255 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 10,577 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01906255 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 10,577 participants
- Enrollment target
Study Summary
This is an observational study of HIV-1 negative individuals who participated in demonstration projects or clinical studies and took daily Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for pre-exposure prophylaxis (PrEP). All individuals were enrolled and followed as described in the parent PrEP demonstration project or clinical study protocol until study completion, HIV-1 infection, discontinuation due to an adverse event, lost to follow-up, or administrative censoring. In the protocols of the parent PrEP observational or clinical studies, participants had follow-up visits on average every 3 months for evaluation of adherence, renal and bone adverse events, and HIV-1 infection status. Adherence was determined by the specific FTC/TDF drug level measurement(s) outlined in the parent protocol. Gilead had collected data from 21 global PrEP demonstration projects and clinical studies for over 7,000 Truvada for PrEP users who had at least one measurement of adherence. Data from the different contributing studies were pooled for statistical analyses by Gilead.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,577 participants |
| Start Date | 2013-10-07 |
| Est. Completion | 2021-04-27 |
What the finished NCT01906255 record still lists
NCT01906255 is an observational study that tracks outcomes without assigning an intervention. Its 10,577 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01906255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01906255 about?
NCT01906255 is a clinical study titled "Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)". This is an observational study of HIV-1 negative individuals who participated in demonstration projects or clinical studies and took daily Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for pre-exposure prophylaxis (PrEP). All individuals were enrolled and followed as described in t...
What is the current status of trial NCT01906255?
This trial is currently completed. The enrollment target is 10,577 participants. The study started on 2013-10-07. Estimated completion is 2021-04-27.
Who is sponsoring clinical trial NCT01906255?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI